Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072716 | 1.00 | GPR119 (0.43) | GPR119STAT3PTGS2JAK2JAK3 | |
| SCHEMBL26072047 | 0.92 | GPR119 (0.45) | GPR119STAT3CCR2 | |
| SCHEMBL31576220 | 0.92 | GPR119 (0.45) | GPR119STAT3CCR2 | |
| SCHEMBL29396269 | 0.92 | GPR119 (0.42) | GPR119STAT3PTGS2 | |
| SCHEMBL26072118 | 0.92 | GPR119 (0.42) | GPR119STAT3PTGS2 | |
| SCHEMBL30442239 | 0.91 | GPR119 (0.42) | GPR119STAT3PTGS2 | |
| SCHEMBL26072673 | 0.91 | GPR119 (0.42) | GPR119STAT3PTGS2 | |
| SCHEMBL31576213 | 0.86 | CCR2 (0.38) | STAT3PTGS2JAK2JAK3PTK2 | |
| SCHEMBL26072351 | 0.86 | CCR2 (0.38) | STAT3PTGS2JAK2JAK3PTK2 | |
| SCHEMBL29395772 | 0.78 | CCR2 (0.44) | JAK2JAK3PTK2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200298-B1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040267-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | disclosed |